SNDXSyndax Pharmaceuticals, Inc.
Price
+11%1YEnd-of-day closes, not the intraday tick.
Survival is the story here: start there
Quality strong, hard red flags, growing in the filings, the market against it.
We are a commercial-stage biopharmaceutical company advancing innovative cancer therapies. We currently have two commercially approved medicines, Revuforj® (revumenib) and Niktimvo (axatilimab-csfr), and a robust slate of clinical development programs designed to unlock the full potential of our first two products. Revuforj is our first-in-class menin inhibitor that was approved by the U.S. Food and Drug Administration, or FDA, in November 2024 for the treatment of relapsed or refractory, or R/R, acute leukemia with a lysine methyltransferase 2A gene, or KMT2A, translocation in adult and pediatric patients one year old and older.
In the company’s own words · 10-K filed Feb 26, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
Syndax Pharmaceuticals, Inc. (SNDX) reported revenue of $73M in Q2 2026 (quarter ended Jun 30, 2026), up 92% from the same quarter a year earlier. That came with net loss of $49M. For the full year FY2025, revenue was $172M (+628% year on year) and net income −$285M. The next results filing is expected around Nov 2, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Aug 4, 2026Syndax Reports Second Quarter 2026 Financial Results and Provides Business Update.Earnings release · press release
- Jul 14, 2026On July 14, 2026, Syndax Pharmaceuticals, Inc. (the “Company”) issued a press release and presentation highlighting its late-stage programs and the next chapter of its R&D strategy, including new pipeline assets, during its R&D event held on July 14, 2026.Other event · Form 8-K
- Jun 10, 2026Entry into a Material Agreement.Material agreement entered · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.